Synthesis and in silico studies of hexahydroacridine derivatives as potential antitumor agents.

Eman A E El-Helw, Sherif F Hammad, Hassan A Khatab, Youssef A Said, Esmail M El-Fakharany, Ahmed I Hashem

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eman A E El-HelwChemistry Department, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt. eman.abdelrahman@sci.asu.edu.eg.

Sherif F HammadPharmaceutical Chemistry Department, Faculty of Pharmacy, Capital University (Formerly Helwan University), Cairo, 11795, Egypt.

Hassan A KhatabChemistry Department, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt. hassankhatab94@gmail.com.

Youssef A SaidBiochemistry Department, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt.

Esmail M El-FakharanyProtein Research Department, Genetic Engineering and Biotechnology Research Institute GEBRI, City of Scientific Research and Technological Applications, New Borg El Arab, 21934, Alexandria, Egypt.

Ahmed I HashemChemistry Department, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt. ahmedhashem1942@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in targeted cancer therapies, drug resistance and off-target toxicity remain major challenges, underscoring the need for new multi-targeted agents with improved selectivity. The present study evaluated the anticancer potential of newly synthesized hexahydro-1,8-acridinedione derivatives featuring strategic structural modifications at positions 9 and 10. The novelty of this work lies in the introduction of N-aryl substituents combined with C-9 biphenyl or 4-bromophenyl groups, a structural motif not previously reported for this chemotype. This dual modification was rationally designed to enhance π-π stacking interactions with kinase ATP-binding pockets while improving metabolic stability through fluorine substitution. Compounds were synthesized via a one-pot multicomponent reaction catalyzed by PTSA and characterized by IR,

Indexed as

AcridinesAntineoplastic AgentsCell Line, TumorDrug Screening Assays, AntitumorErbB ReceptorsHumansMolecular Docking SimulationStructure-Activity RelationshipAcridinesAntineoplastic AgentsErbB Receptors1,8-AcridinedionesAntitumor activityMolecular dockingMulticomponent reactionTelomerase inhibition activity

Identifiers

PMID42717215

DOI10.1038/s41598-026-68544-0

PMCPMC13558586

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.